Innate Pharma S.A. (IPH.PA)
EUR 1.76
(1.27%)
EUR 1.76
(1.27%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -4.12 Million EUR | -103.61% |
| 2022 | -2.02 Million EUR | 94.2% |
| 2021 | -34.89 Million EUR | -164.87% |
| 2020 | 53.79 Million EUR | 125.87% |
| 2019 | 23.81 Million EUR | 130.39% |
| 2018 | 10.33 Million EUR | 130.08% |
| 2017 | -34.36 Million EUR | -556.31% |
| 2016 | 7.53 Million EUR | 162.77% |
| 2015 | -12 Million EUR | -7.33% |
| 2014 | -11.18 Million EUR | -328.63% |
| 2013 | 4.89 Million EUR | 39.16% |
| 2012 | 3.51 Million EUR | -65.21% |
| 2011 | 10.1 Million EUR | 1031.24% |
| 2010 | 893 Thousand EUR | -79.56% |
| 2009 | 4.36 Million EUR | -57.85% |
| 2008 | 10.36 Million EUR | -10.05% |
| 2007 | 11.52 Million EUR | 188.53% |
| 2006 | 3.99 Million EUR | 1021.91% |
| 2005 | 356 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -8.36 Million EUR | -435.22% |
| 2024 Q2 | -8.36 Million EUR | 0.0% |
| 2023 Q4 | -1.56 Million EUR | 0.0% |
| 2023 Q3 | -1.56 Million EUR | -107.97% |
| 2023 Q1 | 4.37 Million EUR | 186.68% |
| 2023 FY | -4.12 Million EUR | -103.61% |
| 2023 Q2 | 19.61 Million EUR | 348.66% |
| 2022 FY | -2.02 Million EUR | 94.2% |
| 2022 Q1 | 10.31 Million EUR | 202.09% |
| 2022 Q2 | 28.79 Million EUR | 179.1% |
| 2022 Q3 | -7.31 Million EUR | -125.39% |
| 2022 Q4 | -5.04 Million EUR | 31.0% |
| 2021 Q1 | -3.94 Million EUR | -117.67% |
| 2021 FY | -34.89 Million EUR | -164.87% |
| 2021 Q3 | -7.2 Million EUR | -460.51% |
| 2021 Q2 | -1.28 Million EUR | 67.45% |
| 2021 Q4 | -10.1 Million EUR | -40.3% |
| 2020 FY | 53.79 Million EUR | 125.87% |
| 2020 Q1 | 2.62 Million EUR | -78.51% |
| 2020 Q4 | 22.34 Million EUR | 577.79% |
| 2020 Q3 | 3.29 Million EUR | -76.61% |
| 2020 Q2 | 14.09 Million EUR | 437.23% |
| 2019 Q2 | 33.29 Million EUR | 195.03% |
| 2019 Q3 | -7.8 Million EUR | -123.43% |
| 2019 Q4 | 12.2 Million EUR | 256.44% |
| 2019 FY | 23.81 Million EUR | 130.39% |
| 2019 Q1 | 11.28 Million EUR | -33.07% |
| 2018 Q1 | -4.66 Million EUR | 26.32% |
| 2018 FY | 10.33 Million EUR | 130.08% |
| 2018 Q4 | 16.86 Million EUR | 0.0% |
| 2018 Q3 | 16.86 Million EUR | 461.6% |
| 2018 Q2 | -4.66 Million EUR | 0.0% |
| 2017 Q1 | -5.15 Million EUR | -161.8% |
| 2017 FY | -34.36 Million EUR | -556.31% |
| 2017 Q4 | -6.32 Million EUR | 0.0% |
| 2017 Q3 | -6.32 Million EUR | -22.79% |
| 2017 Q2 | -5.15 Million EUR | 0.0% |
| 2016 Q2 | 206 Thousand EUR | 0.0% |
| 2016 FY | 7.53 Million EUR | 162.77% |
| 2016 Q4 | 8.34 Million EUR | 0.0% |
| 2016 Q3 | 8.34 Million EUR | 3948.79% |
| 2016 Q1 | 206 Thousand EUR | -87.7% |
| 2015 Q1 | -4.05 Million EUR | 25.97% |
| 2015 FY | -12 Million EUR | -7.33% |
| 2015 Q2 | -4.05 Million EUR | 0.0% |
| 2015 Q4 | 1.67 Million EUR | 0.0% |
| 2015 Q3 | 1.67 Million EUR | 141.27% |
| 2014 Q3 | -5.48 Million EUR | -168.19% |
| 2014 Q1 | -2.04 Million EUR | -197.64% |
| 2014 Q2 | -2.04 Million EUR | 0.0% |
| 2014 Q4 | -5.48 Million EUR | 0.0% |
| 2014 FY | -11.18 Million EUR | -328.63% |
| 2013 Q3 | 2.09 Million EUR | 136.9% |
| 2013 Q1 | 883.5 Thousand EUR | -33.67% |
| 2013 FY | 4.89 Million EUR | 39.16% |
| 2013 Q4 | 2.09 Million EUR | 0.0% |
| 2013 Q2 | 883.5 Thousand EUR | 0.0% |
| 2012 Q4 | 1.33 Million EUR | 0.0% |
| 2012 FY | 3.51 Million EUR | -65.21% |
| 2012 Q3 | 1.33 Million EUR | 0.0% |
| 2011 FY | 10.1 Million EUR | 1031.24% |
| 2010 FY | 893 Thousand EUR | -79.56% |
| 2009 FY | 4.36 Million EUR | -57.85% |
| 2008 FY | 10.36 Million EUR | -10.05% |
| 2007 FY | 11.52 Million EUR | 188.53% |
| 2006 FY | 3.99 Million EUR | 1021.91% |
| 2005 FY | 356 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 766.828% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 205.289% |
| Adocia SA | 1.38 Million EUR | 397.545% |
| Aelis Farma SA | 12.35 Million EUR | 133.347% |
| Biophytis S.A. | -803 Thousand EUR | -413.2% |
| Advicenne S.A. | 1.42 Million EUR | 388.99% |
| genOway Société anonyme | 20.1 Million EUR | 120.502% |
| IntegraGen SA | 5.01 Million EUR | 182.12% |
| Medesis Pharma S.A. | -2.66 Million EUR | -54.648% |
| Neovacs S.A. | 29.31 Thousand EUR | 14158.129% |
| NFL Biosciences SA | -56.06 Thousand EUR | -7250.528% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 291.415% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | -190.357% |
| Sensorion SA | 3.78 Million EUR | 208.795% |
| Theranexus Société Anonyme | -4.63 Million EUR | 11.16% |
| TME Pharma N.V. | -127 Thousand EUR | -3144.882% |
| Valbiotis SA | 2.66 Million EUR | 254.46% |
| TheraVet SA | -530.79 Thousand EUR | -676.381% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 425.257% |
| DBV Technologies S.A. | 4.15 Million EUR | 199.072% |
| Genfit S.A. | 28.22 Million EUR | 114.601% |
| GeNeuro SA | -293.8 Thousand EUR | -1302.655% |
| Inventiva S.A. | 17.5 Million EUR | 123.549% |
| MaaT Pharma SA | 1.65 Million EUR | 349.003% |
| MedinCell S.A. | 9.28 Million EUR | 144.369% |
| Nanobiotix S.A. | 36.2 Million EUR | 111.381% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 285.047% |
| Poxel S.A. | 1000.00 EUR | 412200.0% |
| GenSight Biologics S.A. | 3 Million EUR | 237.367% |
| Transgene SA | -28.4 Million EUR | 85.491% |
| Valneva SE | 52.83 Million EUR | 107.799% |